scholarly journals rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

2019 ◽  
Vol Volume 11 ◽  
pp. 8371-8377
Author(s):  
Jun Zhu ◽  
Si-Guo Hao ◽  
Jiong Hu ◽  
Jing-Li Zhuang ◽  
Chun Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Peripheral Blood ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Peripheral Blood Stem Cells ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Blood Stem Cells

Long-Term Results of a Phase-I/II Study of Sequential High-Dose Chemotherapy with Autologous Stem Cell Transplantation in the Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

2007 ◽  
Vol 93 (5) ◽  
pp. 409-416 ◽  
Author(s):  
Anja Welt ◽  
Philipp Schütt ◽  
Cordula Derks ◽  
Peter Ebeling ◽  
Siemke Müller ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
High Dose Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Long Term Results ◽  
High Dose ◽  
Peripheral Blood Stem Cells ◽  
Conventional Dose ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Blood Stem Cells

Aims and Background To improve the survival of patients with aggressive non-Hodgkin's lymphoma, we evaluated a risk-adapted therapeutic approach using high-dose (HD) or conventional-dose (CD) chemotherapy (CT) for poor-risk and good-risk patients, respectively. Methods Twenty patients were treated in each group. In both groups, the first chemotherapy cycle consisted of dexamethasone, vincristine, ifosfamide, and etoposide. Thereafter, the CD or HD patients received 3 or 2 cycles of dexamethasone, vincristine, epirubicin, and cyclophosphamide, respectively, followed by 1 cycle of dexamethasone, carboplatin, and etoposide. In the HD group cyclophosphamide, epirubicin, carboplatin, and etoposide were dose-escalated by a factor of 6, 3, 3, and 3, respectively, as compared to the CD group, and autologous peripheral blood stem cells were administered after each HD-CT cycle. Results Grade III-IV toxicities were neutropenia and thrombocytopenia (100%), anemia (55%), and stomatitis (30%) in patients with HD-CT, and neutropenia (90%) in patients with CD-CT. One toxic death occurred in a patient with HD-CT. The overall response rate was 100% in HD-CT patients, including 70% complete remissions, and 80% in CD-CT patients, including 60% complete remissions. The 10-year overall survival was 55% for patients with HD-CT and 80% for patients with CD-CT. Conclusions The risk-adapted treatment approach showed tolerable toxicities and was associated with encouraging results.

Sign in / Sign up

Export Citation Format

Share Document